Pro- and antioxidant processes in schizophrenics with tardive dyskinesia;Procesy pro- i antyoksydacyjne u osób chorych na schizofreniȩ z objawami późnych dyskinez

Psychiatria Polska

Volumn 39, Issue 6, 2005, Pages 1131-1141

  Gałecki, Piotr ^a   Pietras, Tadeusz ^b   Florkowski, Antoni ^a  

^a Klinika Psychiatrii i Zaburze Nerwicowych   (Poland)

^b Medical University of Lodz Klinika Pneumonologii i Alergologii   (Poland)

Author keywords

Oxidative stress; Schizophrenia; Tardive dyskinesia

Indexed keywords

CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; LIPID PEROXIDASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PARANOID SCHIZOPHRENIA; PATHOGENESIS; TARDIVE DYSKINESIA;

EID: 31044450439     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term out-patients maintained with neuroleptic medications. Arch Gen Psychiatry 1993; 50: 723-733.
2. Goldberg RJ. Tardive dyskinesia in elderly patients: an update. J. Am. Med. Dir. Assoc. 2002; 3: 152-161.
3. Waddington JL, Youssef HA. Lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs. Brit. J. Psychiatry 1990; 156: 106-108.
4. Jenner P, Marsden CD. Is the dopamine hypothesis of tardive dyskinesia completely wrong? Trends Neurosc. 1986; 9: 259-260.
5. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic induced movement disorders: evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sc. 1989; 570: 176-185.
6. Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosc. 1986; 9: 107-108.
7. Coyle JT, Puttfacken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 289-295.
8. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM. Prospective study of tardive dyskinesia incidence in the olderly. JAMA 1991; 266: 2402-2406.
9. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 1992; 59: 1609-1623.
10. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: A comparison of the CuZnSOD (sod1), Mn-SOD (sod2), and EC-SOD (sod3) gene structures, evolution, and expression. Free Radic. Biol. Med. 2002; 33: 337-349.
11. Barradas MA, Mikhailidis DP. The use of platelets as models for neurons: possible applications to the investigation of eating disorders. Biomed Pharmacother. 1993; 47: 11-18.
12. Dreux C, Launay JM. Blood platelets: neuronal model in psychiatric disorders. Encephale 1985; 11: 57-64.
13. Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Hum. Psychopharmacol. 2001; 16: 229-236.
14. Malmgren R, Hasselmark L. The platelet and the neuron: two cells in focus in migraine. Cephalalgia 1988; 8: 7-24.
15. Klasyfikacja zaburzeń psychicznych i zaburzeń zachowania w ICD-10. Opisy kliniczne i wskazówki diagnostyczne. Kraków, Warszawa: Uniwersyteckie Wydawnictwo Medyczne "Vesalius"; 1997.
16. Kay SR, Opler LA. Positive and Negative Syndrome Scale (PANSS) rating manual. San Rafael CA: Social and Behavioral Sciences Documents; 1987.
17. Simpson GH, Angus JW. A rating scale for extrapiramidal side effect. Acta. Psychiatr. Scand. 1970; 212: 11-19.
18. Placer Z., Cushman L. Johnson B. Estimation of product of lipid peroxidation malondialdehyde in biochemical systems. Anal. Bioch. 1966; 16: 359-364.
19. Little C, O'Brian P. Intracellular GSH-peroxidase with a lipid peroxidase substrate. Biophis. Res. Commun. 1968; 31: 145-150.
20. Beers R, Sizer T. Spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J. Biol. Chem. 1952; 195: 133-140.
21. Misra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972; 247: 3170-3175.
22. Rosen DR. Mutation Cu/Zn superoxide dismutase gene are assosiated with familiar amylotrophic lateral sclerosis. Nature 1993; 352: 59-62.
23. Tsai G, Coyle JT. N-Acetyaspartate in neuropsychiatric disorders. Progr. Neurobiol. 1995; 46: 531-540.
24. Tsai G, Goff D, Chang R, Flood J, Baer L, Coyle J. Markers of glutamatergic neurotransmission and oxidative stress assosiated with tardive dyskinesia. Am. J. Psychiatry 1998; 155: 1207-1213.
25. Jeste DV, Lohr JB, Manley M. Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacol. 1992; 106: 154-160.
26. Ossowska K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol. J. Pharmacol. 2002; 54: 299-312.
27. Weinberger DR. From neuropathology to neurodevelopment. Lancet 1995; 346: 552-557.
28. Kahl R, Kampkotter A, Watjen W, Chovolou Y. Antioxidant enzymes and apoptosis. Drug Metab. Rev. 2004; 36: 747-762.
29. Herrlich P, Bohmer FD. Redox regulation of signal transduction in mammalian cells. Biochem. Farmacol. 2000; 59: 35-41.
30. Kuloglu M, Ustundag B, Atmaca M. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Funct. 2002; 20: 171-175.
31. Petronijevic ND, Micic DV, Duricic B. Substrate kinetics of erythrocyte membrane NaK-ATPase and lipid peroxides in schizophrenia. Progr. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 431-440.
32. Srivastava N, Barthwal MK, Dalal PK. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacol. 2001; 158: 140-145.
33. Arvindakshan M, Sitasawad S, Debsikder V. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 2003; 53: 56-64.
34. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid paroxidation and peroxidative tissue injury. Free Radic. Biol. Med. 1990; 9: 515-540.
35. Yim MB, Chock PB, Stadtman ER. Enzyme function of cooper, zinc superoxide dismutase as a free radical generator. J. Biol. Chem. 1993; 268: 4099-4105.
36. Akyd O, Herken H, Uz E. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Progr. Neuropharmacol. Biol. Psychiatry 2002; 26: 995-1005.
37. Yao JK, Reddy R, McElhinny LG. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiatr. Res. 1998; 32: 385-391.
38. Mukerjee S, Mahadik SP, Scheffer R. Impaired antioxidant defense at the onset of psychosis. Schizophr. Res. 1996; 19: 19-26.
39. Parikh V, Khan MM, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2003; 37: 43-51.
40. Andreassen OA, Finsen B, West MJ, Jorgensen HA. Reduced number of striatal neurons expressing preprosomatostatin mRNA in rats with oral dyskinesias after long term haloperidol administration. Neurosc. Lett. 2000; 279: 21-24.
41. Mitchel J, Cooper AC, Griffits MR, Cooper AJ. Acute administration of haloperidol induces apoptosis of neurons in the striatum and substantia nigra in the rat. Neurosc. 2002; 109: 89-99.
42. Qing H, Xu H, Wei Z. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur. J. Neurosc. 2003; 17: 1563-1570.
43. Zhang XY, Zhou DF, Cao LY. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J. Clin. Psychopharmacol. 2003; 23: 128-131.
44. Wei Z, Bai O, Richardson JS. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosc. Res. 2003; 73: 364-368.
45. Balijepalli S, Boyd MR, Ravindranath V. Inhibition on mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacol. 1999; 38: 567-577.
46. Pietras T. Udział nieprawidłowej czynności lańcucha oddechowego mitochondriów w patogenezie schizofrenii. Post. Psychiatr. Neurol. 2004; 13: 135-144.
47. Brown K, Reid A, White T. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol. Psychiatry 1998; 43: 863-867.
48. Gałecki P, Nowakowski T. Trace elements (copper, zinc) content and superoxide dismutase activity in erythrocytes from schizophrenic patients. Acta Psychiatr. Scand. 2004 (supl.); 421: 14.
49. Zhang XY, Zhou DF, Cao LY. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res. 2003; 62: 245-250.
50. Gu W, Zhao H, Yenari MA, Sapolsky RM, Steinberg GK. Catalase over-expression protects striatal neurons from transient focal cerebral ischemia. Neurorep. 2004; 15: 413-416.
51. Sohal RS, Sohal BH, Brunk UT. Realtionship between antioxidant defences and longevity in different mammalian species. Mech Ageing Dev. 1990; 53: 217-227.